Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDYWM8)

Drug Name
E-10030 Drug Info
Synonyms
PDGF-B antagonist (AMD), Eyetech/Archemix; PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), (OSI) Eyetech/Archemix
Indication
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDYWM8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Platelet-derived growth factor B (PDGFB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PDGF-BB DMMBC5W Diabetic foot ulcer BD54 Phase 3 [3]
GAM-501 DMAEWS1 Diabetic foot ulcer BD54 Phase 2 [4]
CR-002 DMKWSFI Cystic fibrosis CA25 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor B (PDGFB) TTQA6SX PDGFB_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT01089517) A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration. U.S. National Institutes of Health.
2 Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50.
3 Clinical pipeline report, company report or official report of Adocia.
4 Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009 Nov-Dec;17(6):772-9.
5 A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44.